Tissue-based immune monitoring I: Tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment

Cancer Biology and Therapy

Volumn 12, Issue 4, 2011, Pages 357-366

  Hagemann, Andrea R ^a   Cadungog, Mark ^a   Hagemann, Ian S ^a   Hammond, Rachel ^a   Adams, Sarah F ^a   Chu, Christina S ^a   Rubin, Stephen C ^a   Zhang, Lin ^a   Addya, Kathakali ^a   Birrer, Michael J ^b   Gimotty, Phyllis A ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Gene expression profiling; Immunohistochemistry; Lymphocytes; Ovarian neoplasms; Tumor infiltrating

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; FEASIBILITY STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MICROARRAY ANALYSIS; NEEDLE BIOPSY; OVARY CANCER; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR MICROENVIRONMENT;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; BIOPSY, NEEDLE; FEASIBILITY STUDIES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; FROZEN SECTIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MONITORING, IMMUNOLOGIC; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; OVARY; RECEPTORS, ANTIGEN, T-CELL; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84860388990     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.4.16951     Document Type: Article

References (29)

1. Brill T.H., Kubler H.R., Pohla H., Buchner A., Fend F., Schuster T., et al. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 2009; 20:1641-51; PMID:19671000; DOI:10.1089/hum.2009.101.
2. Redfern C.H., Guthrie T.H., Bessudo A., Densmore J.J., Holman P.R., Janakiraman N., et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107-12; PMID:16754937; DOI:10.1200/JCO.2005.04.4289.
3. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley ME Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 2008; 8:299-308; PMID:18354418; DOI:10.1038/nrc2355.
4. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; DOI:10.1038/nm1093.
5. Croci D.O., Zacarias Fluck M.F., Rico M.J., Matar P., Rabinovich G.A., Scharovsky OG Dynamic crosstalk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment Cancer Immunol Immunother 2007; 56:1687-700; PMID:17571260; DOI:10.1007/s00262-007-0343-y.
6. Rosenberg S.A., Yang J.C., Restifo NP Cancer immunotherapy: moving beyond current vaccines Nat Med 2004; 10:909-15; PMID:15340416; DOI:10.1038/nm1100.
7. Leffers N., Lambeck A.J., Gooden M.J., Hoogeboom B.N., Wolf R., Hamming I.E., et al. Immunization with a p53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009; 125:2104-13; PMID:19621448; DOI:10.1002/ijc.24597.
8. Chianese-Bullock K.A., Irvin W.P. Jr, Petroni G.R., Murphy C., Smolkin M., Olson W.C., et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31:420-30; PMID:18391753; DOI:10.1097/CJI.0b013e31816dad10.
9. + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67:7487-94; PMID:17671219; DOI:10.1158/0008-5472.CAN-07-0565.
10. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; DOI:10.1056/NEJMoa020177.
11. Adams S.F., Levine D.A., Cadungog M.G., Hammond R., Facciabene A., Olvera N., et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115:2891-902; PMID:19472394; DOI:10.1002/cncr.24317.
12. Clarke B., Tinker A.V., Lee C.H., Subramanian S., Van de Rijn M., Turbin D., et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss. Mod Pathol 2009; 22:393-402; PMID:19060844; DOI:10.1038/modpathol.2008.191.
13. + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104:3360-5; PMID:17360651; DOI:10.1073/pnas.0611533104.
14. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-43; PMID:16344461; DOI:10.1073/pnas.0509182102.
15. Shah C.A., Allison K.H., Garcia R.L., Gray H.J., Goff B.A., Swisher EM Intratumoral T cells, tumor-associated macrophages and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer Gynecol Oncol 2008; 109:215-9; PMID:18314181; DOI:10.1016/j.ygyno.2008.01.010.
16. Tomšová M., Melichar B., Sedlakova I., Steiner I Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecol Oncol 2008; 108:415-20; PMID:18037158; DOI:10.1016/j.ygyno.2007.10.016.
17. Stumpf M., Hasenburg A., Riener M.O., Jutting U., Wang C., Shen Y., et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 2009; 101:1513-21; PMID:19861998; DOI:10.1038/sj.bjc. 6605274.
18. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-5136; PMID:11431351.
19. Schumacher K., Haensch W., Roefzaad C., Schlag P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61:3932-3936; PMID:11358808.
20. Vesalainen S., Lipponen P., Talja M., Syrjanen K Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma Eur J Cancer 1994; 30:1797-803; PMID:7880609; DOI:10.1016/0959-8049(94)E0159-2.
21. Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L., et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74:492-501; PMID:9355970; DOI:10.1002/(SICI)1097-0215(19971021)74: 5⟨492::AID-IJC3⟩3.0.CO;2-Z.
22. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-3494; PMID:9721846.
23. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; DOI:10.1126/science.1129139.
24. Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; DOI:10.1056/ NEJMoa051424.
25. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001; 7:1127-1135; PMID:11350875.
26. Dudley M.E., Rosenberg SA Adoptive cell transfer therapy Semin Oncol 2007; 34:524-31; PMID:18083376; DOI:10.1053/j.seminoncol.2007.09.002.
27. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20:143-8; PMID:11821859; DOI:10.1038/nbt0202- 143.
28. Donninger H., Bonome T., Radonovich M., Pise-Masison C.A., Brady J., Shih J.H., et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23:8065-77; PMID:15361855; DOI:10.1038/sj.onc.1207959.
29. Calza S., Valentini D., Pawitan Y Normalization of oligonucleotide arrays based on the least-variant set of genes BMC Bioinformatics 2008; 9:140; PMID:18318917; DOI:10.1186/1471-2105-9-140.